News

Combination of Empiriko’s chemosynthetic livers and Interchim’s innovative instrumentation and expertise in the field of liquid chromatography allows pharmaceutical scientists to predict metabolism patterns, pathways and profiles, while

A second NOA has been received for US Patent Application Serial No. 11/782,838 entitled ‘Controlled-release pharmaceutical tablets’ which is related to the drug delivery technology used in Forfivo

The call for proposals comes after newly released recommendations from the Society for Healthcare Epidemiology of America (SHEA) shed light on the issue of contaminated healthcare personnel apparel

The allowed claims for US Patent Application No. 12/528,690 entitled ‘Composition and Methods for Modulating Cell Proliferation and Cell Death’, cover a core element of Rosetta Genomics’ microRNA

The patent covers the company’s carbohydrate-based galectin inhibitor compound GR-MD-02 for use in patients with fatty liver disease with or without fibrosis or cirrhosis, providing patent protection through

The patent covers all of the company’s therapeutic antibodies, and can also be applied to most other antibodies, permitting a concentrated formulation to be given in low volume

The company is replacing a mix of highly customized solutions built on an outdated legacy platform with Veeva Systems’ suite of applications, spanning from clinical to commercial. The

In June 2013, the three parties have collaborated on to build the new center to address increasing demand from pharmaceutical and other Iife science companies for comprehensive imaging

Primary endpoint of the trial is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at six weeks, while secondary endpoints include endoscopic remission, reduction in UCDAI at